Rosacea Treatment Recommendations
For rosacea management, use a phenotype-directed approach: treat mild-to-moderate inflammatory papules/pustules with topical azelaic acid or ivermectin as first-line therapy, persistent erythema with topical brimonidine, and reserve oral doxycycline 40 mg for moderate-to-severe inflammatory disease or therapy-resistant cases. 1
Treatment Algorithm by Clinical Phenotype
The ROSCO international consensus panel established a phenotype-led treatment framework that should guide your therapeutic decisions 1:
Inflammatory Papules and Pustules
Mild disease:
- Topical azelaic acid, ivermectin, or metronidazole are first-line options 1
- These agents target the inflammatory and microbial components of rosacea
Moderate disease:
- Topical azelaic acid or ivermectin remain preferred 1
- Consider adding oral doxycycline if topical therapy proves insufficient
Severe disease:
- Oral doxycycline 40 mg (sub-antimicrobial dose) is superior to placebo and non-inferior to doxycycline 100 mg 1
- Topical ivermectin can be used concurrently 1
- Oral isotretinoin is reserved for refractory cases 1
The German S2k guideline reinforces these recommendations, specifically endorsing low-dose doxycycline as the systemic drug of choice, with low-dose isotretinoin as an alternative 2.
Persistent Erythema
First-line treatment:
- Topical brimonidine (α-adrenergic agonist) provides vasoconstriction for symptomatic relief 1, 2
- Intense pulsed light (IPL) offers more durable improvement for vascular components 1
- Oral doxycycline has evidence for persistent erythema beyond its anti-inflammatory effects 1
Transient Erythema (Flushing)
Treatment options include:
Important caveat: The panel notes there is no high-quality evidence for flushing treatments; these recommendations are based on case reports and clinical experience 1.
Telangiectasia
- Electrodesiccation, IPL, or lasers are the primary interventions 1
- These are procedural rather than pharmacological approaches
Phymatous Rosacea
Clinically inflamed (active) phyma:
- Oral doxycycline 1
Clinically non-inflamed (fibrotic) phyma:
Combination Therapy Approach
For moderate-to-severe disease, combine topical and oral medications 3. The evidence supports using:
- Topical agents (metronidazole, azelaic acid, or ivermectin) PLUS
- Oral doxycycline or minocycline for enhanced efficacy
Recent additions to the therapeutic armamentarium include topical oxymetazoline (another vasoconstrictor), minocycline foam, and microencapsulated benzoyl peroxide 5% cream with improved tolerability 4.
Essential Adjunctive Measures
All patients require:
- SPF 30+ sun protection 1
- Gentle cleansers and moisturizers 1
- Trigger avoidance (identify and eliminate individual triggers) 1, 3
These non-pharmacological interventions are fundamental to preventing exacerbations and should not be overlooked 3.
Common Pitfalls to Avoid
Do not use high-dose antibiotics when low-dose formulations suffice. Doxycycline 40 mg provides equivalent efficacy to 100 mg for rosacea while minimizing antibiotic resistance and microbiome disruption 1. Sarecycline offers a narrower antibacterial spectrum, potentially reducing these concerns further 4.
Do not treat all rosacea the same way. The phenotype-directed approach is critical—treating persistent erythema with antibiotics alone or inflammatory lesions with vasoconstrictors alone will yield suboptimal results 1.
Recognize that topical brimonidine and oxymetazoline provide symptomatic relief only, not disease modification. They address erythema temporarily through vasoconstriction but do not treat underlying inflammation 2, 4.
Emerging Evidence
Newer therapeutic targets under investigation include mast cell stabilization (hydroxychloroquine, intradermal botulinum toxin A), immunomodulation (tofacitinib), and microbiome-directed therapies including Demodex eradication and Helicobacter pylori treatment 4, 5. However, these remain investigational and the clinical pipeline for rosacea appears limited, particularly for refractory and phymatous disease 4.